Search results for Vaccine-induced+prothrombotic+immune+thrombocytopenia%3A+pathogenetic+and+epidemiological+issues+of+concern - 4212 results

news

Bristol Myers Squibb acquires cell therapy biotech Orbital for $1.5bn

14 October 2025 | By Dominic Tyer (European Pharmaceutical Review)

Gains access to OTX-201, a preclinical CAR T therapy being developed to treat autoimmune diseases.

article

Vaccine-induced prothrombotic immune thrombocytopenia: pathogenetic and epidemiological issues of concern

5 May 2021 | By Giovanni Di Guardo DVM Dipl. ECVP

Giovanni Di Guardo, DVM, Dipl. ECVP, retired Veterinary Pathologist, discusses the association between adenoviral vector COVID-19 vaccines and rare blood clots, outlining four areas warranting further research.

news

INO-4800 COVID-19 vaccine provides cross-reactive immune responses against variants

19 April 2021 | By Hannah Balfour (European Pharmaceutical Review)

Antibodies induced by the investigational DNA vaccine candidate, INO-4800, were found to be able to neutralise three SARS-CoV-2 emerging variants of concern.

news

COVID-19 vaccine safely induces immune response in Chinese trial

21 July 2020 | By Hannah Balfour (European Pharmaceutical Review)

Investigators report CanSino Biologics’ Ad5-nCoV vaccine induced antibody production with mild to moderate side effects in patients.

news

COVID-19 vaccine induces immune response in Phase I trial

26 May 2020 | By Hannah Balfour (European Pharmaceutical Review)

The adenovirus type 5 vectored COVID-19 (Ad5-nCoV) vaccine candidate safely induced T cell and antibody responses in 108 adults.

news

Janssen COVID-19 Vaccine can protect against variants of concern

10 June 2021 | By Hannah Balfour (European Pharmaceutical Review)

Trial shows the single-shot Janssen COVID-19 Vaccine generates robust immune responses against several COVID-19 variants.

news

Intranasal influenza vaccine produces strong immune response, Phase I study shows

4 February 2021 | By Victoria Rees (European Pharmaceutical Review)

A Phase I clinical trial has shown that Ad4-H5-VTN, a single-dose, intranasal influenza vaccine, was safe and produced an immune response.

news

J&J’s Ebola vaccine regimen demonstrates immune response

15 September 2021 | By Anna Begley (European Pharmaceutical Review)

Johnson & Johnson’s Ebola vaccine regimen, Zabdeno® and Mvabea®, generated robust humoral immune responses in adults and children.

news

Oxford Vaccine Group initiates Phase 2 study of Ebola prime-boost vaccine regimen combining MVA-BN-Filo and Ad26.ZEBOV

15 July 2015 | By Victoria White

Oxford Vaccine Group has initiated a Phase 2 clinical study of the Ebola prime-boost vaccine regimen that combines MVA-BN-Filo with Ad26.ZEBOV...

news

COVID-19 Vaccine Moderna effective against variants of concern

16 September 2021 | By Anna Begley (European Pharmaceutical Review)

New data shows that Moderna’s COVID-19 vaccine protects against variants of concern and reduces breakthrough infection risk.

Whitepapers/App Notes/Posters

Whitepaper: Multiplexed cancer immune response analysis nCounter® PanCancer Immune Profiling Panel for gene expression

1 October 2015 | By nanoString

The ability of mutated cells to give rise to pathological cancer relies upon the capability of these cells to evade immune recognition, suppress immune activity, and persist in a chronically inflamed environment. Tremendous growth in the understanding of these complex processes is beginning to generate breakthroughs in the treatment of…

news

Revolade shows long-term disease control for immune thrombocytopenia

18 October 2017 | By Dr Zara Kassam (European Pharmaceutical Review)

Novartis has announced long-term study results supporting the positive safety and efficacy of Revolade in adults with chronic/persistent immune thrombocytopenia...

news

Virus-like particle vaccine protects against RSV vaccine-enhanced respiratory disease

24 November 2017 | By Dr Zara Kassam (European Pharmaceutical Review)

Researchers have discovered that a virus-like particle vaccine can prime the body's immune response and prevent the severe respiratory diseases...

news

Sanofi Pasteur’s Fluzone High-Dose vaccine significantly more effective than standard dose Fluzone vaccine in preventing influenza

26 August 2013 | By Sanofi Pasteur

“We are pleased that this study demonstrates the superior relative efficacy of Fluzone High-Dose vaccine..."

news

Panacea initiates Phase I prostate cancer vaccine therapy trial

19 January 2017 | By Niamh Marriott, Digital Editor

Panacea Pharmaceuticals have enrolled and dosed the first patient in the open-label, parallel designed, multi-centre Phase I clinical trial of PAN-301-1, for the treatment of persistent prostate cancer to assess safety and immunogenicity. Clinical sites for the PAN-301-1 trial are located in Alabama, California, Nebraska and South Carolina and the…